Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7022010

CCCN1CCCCC1.Cl

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 known ✓ Q9Y5N1 1/20 0.52
DRD2 known ✓ P14416 2/20 0.40
SIGMAR1 known ✓ Q99720 1/20 0.40
DRD1 known ✓ P21728 1/20 0.38
DRD4 known ✓ P21917 1/20 0.38
DRD3 known ✓ P35462 1/20 0.38
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CYP1A2 P05177 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LTA4H P09960 1/20 0.38
DRD5 P21918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL713346 0.97
SCHEMBL2745438 0.97
SCHEMBL81143 0.97
SCHEMBL14926143 0.97 HRH3 (0.55) HRH3CARM1PRMT6PRMT8ALDH1A1
SCHEMBL19250122 0.97 HRH3 (0.55) HRH3CARM1PRMT6PRMT8ALDH1A1
SCHEMBL23600074 0.97 HRH3 (0.55) HRH3CARM1PRMT6PRMT8ALDH1A1
SCHEMBL1685364 0.97 HRH3 (0.55) HRH3CARM1PRMT6PRMT8ALDH1A1
Fluoride SCHEMBL1963693 0.94 HRH3 (0.52) HRH3CARM1PRMT6PRMT8ALDH1A1
Iodide SCHEMBL8060471 0.94 HRH3 (0.52) HRH3CARM1PRMT6PRMT8ALDH1A1
Bromide SCHEMBL1961470 0.94 HRH3 (0.52) HRH3CARM1PRMT6PRMT8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109988115-A A kind of double basic functionalized ionic liquids and preparation method thereof with surface-active 枣庄学院 2019-07-09 CN claimed
CN-108069892-A A kind of preparation method of 4-acetoxyl group piperidine hydrochlorate 盐城师范学院 2018-05-25 CN claimed
WO-2023214412-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2023-11-09 WO disclosed
CN-106883196-B A kind of synthetic method of first piperazine raw medicine 中棉小康生物科技有限公司 2019-03-22 CN disclosed
CN-108069892-A A kind of preparation method of 4-acetoxyl group piperidine hydrochlorate 盐城师范学院 2018-05-25 CN disclosed
CN-105801580-B For synthesizing the intermediate of BI 1356, its preparation method and the preparation method of BI 1356 无锡佰翱得生物科学有限公司 2018-04-20 CN disclosed
US-9731012-B2 Laser-actuated therapeutic nanoparticles PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-08-15 US disclosed
CN-106883196-A A kind of synthetic method of first piperazine active compound 安阳市小康农药有限责任公司 2017-06-23 CN disclosed
EP-3160470-A1 ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE Teva Pharmaceutical Industries Ltd (IL) 2017-05-03 EP disclosed
WO-2016003919-A1 ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2016-01-07 WO disclosed
US-20150065685-A1 LASER-ACTUATED THERAPEUTIC NANOPARTICLES PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-03-05 US disclosed
EP-1274430-A2 COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME PHARMACIA & UPJOHN COMPANY (US) 2003-01-15 EP disclosed
WO-2001081343-A2 COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME PHARMACIA & UPJOHN COMPANY (US) 2001-11-01 WO disclosed
CN-1044365-C Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis SANKYO CO (JP) 1999-07-28 CN disclosed